Purpose Pulverized konjac glucomannan (PKGM) is a natural biologically active compound extracted from konjac, a Japanese traditional food. In the present study, we investigated the role of PKGM in intestinal immunity in a mouse model of oxazolone (OXA)-induced colitis. Methods C57BL/6(B6) mice were fed PKGM or control food from 2 weeks before the induction of OXA colitis. Body weight change, colon length, and histological change in the colon were examined. The mononuclear cells were purified from colon and stimulated with PMA/ionomycin. The levels of TNF-a, interferon (IFN)-c, interleukin (IL)-4, and IL-13 from the supernatant were measured by ELISA. Results Oral administration of PKGM prevented the body weight loss and shortening of colon length associated with OXA-induced colitis. Histological analysis revealed that the colonic inflammation was improved by the administration of PKGM. The levels of IL-4 and IL-13, the critical inflammatory cytokines in OXA colitis, derived from mononuclear cells from the lamina propria of the colon were significantly suppressed by PKGM administration. PKGM-fed mice showed a significantly lower IL-4/IFN-c ratio in the colonic lamina propria compared with that in control-fed mice. Fluorescence-activated cell sorting analysis revealed that natural killer (NK) 1.1
Introduction
Ulcerative colitis (UC) is a chronic inflammatory disorder of the colon, but its etiology is far from being understood in detail. Despite various treatments for UC, patients do not recover completely and frequently undergo repeat relapse and remission. Although the mechanisms underlying UC are not poorly understood, much of the chronic inflammation of the colon that characterizes this disease is thought to be due to inappropriate activation of the immune system [1] [2] [3] .
Currently, patients with UC are usually treated with 5-aminosalicylic acid and/or corticosteroids. However, the prolonged use of corticosteroids may be limited by potential adverse effects, such as osteoporosis, fracture, infection, and cataracts. Various alternative pharmacological approaches have been put forward to decrease the dosage of steroids to decrease their side effects [4] .
Konjac is a glucomannan-rich Japanese traditional food, which is derived from the tubers of Amorphophallus konjac, and has been consumed traditionally in Asia. Konjac glucomannan (KGM) is a highly viscous polysaccharide composed of glucose and mannose residues at a molar ratio of 1:1.6 joined through b1,4-glucosidic linkages. It has proved to be a health or dietary food due to its watersoluble fibers. Numerous clinical studies have been published on KGM, which ameliorates glycemia and other associated risk factors for coronary heart disease in type 2 diabetes [5] and delays the absorption of both cholesterol and triglyceride from the small intestine [6] . Moreover, KGM is effective on intestine by modulating cecal and fecal microflora in mice [7] , and it inhibits carcinogenesis in rat [8] . However, the precise mechanisms underlying the immunologic effects of KGM remain largely unclear.
Nutritional supplementation with highly viscous KGM is restricted on account of its low solubility, which requires long time intervals to attain peak viscosity. To circumvent this restriction, we prepared highly specific surface area of the KGM molecule that would be expected to possess some extent of these well-known physiological activities [9] . To investigate the immunomodulating potency of low-viscous KGM, several particle sizes of pulverized KGM (PKGM) were used in NC/Nga mice, a murine model for human AD [10] . Production of hyper-IgE and inflammatory cytokines was suppressed in the PKGM-fed mice, and AD-like skin symptoms were markedly suppressed by oral intake of PKGM [11, 12] . There are several studies on the effects of carbohydrates like inulin, galactomannan, and glucomannan in the form of KGM [13, 14] . So far, however, there have been no reports demonstrating the effect of PKGM on intestinal inflammation.
Experimental animal models are indispensable for the accurate understanding of the pathogenesis of human diseases. Support for this view may be drawn from animal models of colitis, which consistently exhibit an imbalance of regulatory and inflammatory cytokines. Rectal instillation of the haptenating reagent oxazolone (OXA) leads to rapid development of colitis limited to the distal half of the colon. The histologic features and distribution of OXA colitis have characteristics that resemble those of UC [15] . The inflammation is characterized by increased secretion of IL-4 and IL-5 and can be ameliorated by the administration of anti-IL-4 monoclonal antibodies [15] . Therefore, this model has been used to study the contribution of the Th2-dependent immune response to intestinal inflammation.
IL-13 seems to be a key pathogenic cytokine of OXA colitis because IL-13 neutralization prevents its development [16] . IL-13 is known as an inflammatory cytokine and is considered a growth factor for epithelial cells in asthma [17] . Recently, it has been reported that IL-13 is also critical for the pathogenesis of UC [18] . Therefore, IL-13 may be a candidate for the treatment of UC. IL-13 is produced by iNK Tcells in OXA colitis in mice [16] and by non-invariant NKT cells in UC [19] .
In the present study, we report that dietary PKGM was effective in reducing inflammation in OXA colitis in mice. We show that PKGM reduced colonic inflammation and suppressed the mediators of both innate and adaptive immunity. Mechanistic studies carried out using mononuclear cells derived from intestinal lamina propria show that PKGM effectively regulates the function of effector T cells by shifting from a Th2-to a Th1-dependent immune response.
Materials and methods

KGM powders
Two kinds of low-viscous KGM powders, PA (PROPOL Ò ; Shimizu Chemical Corporation, Hiroshima, Japan) and pulverized PA (PKGM) (Nishikawa Rubber Corporation, Hiroshima, Japan), were used in this study. The GM contents were measured to be approximately 99 % for PA and 97 % for PKGM. The mean particle sizes of the KGM powders were estimated to be about 300 lm for PA and 105 lm for PKGM. The peak velocity of the 1 % PA solutions reached more than 100,000 mPa s after 7 h at 25°C, while that of PKGM solutions attained values of 32,000-35,000 mPa s within 0.5 h.
Animals
Female C57BL/6(B6) mice (6-8 weeks old) were purchased from CLEA JAPAN (Tokyo, Japan). Female Ja281-deficient [Va14NKT cell-deficient (KO)] mice on B6 background (6-10 weeks old) were generated as described previously [20] . Mice were divided into eight groups in clear plastic cages with a mesh top under specific pathogen-free conditions, kept at room temperature in a controlled environment at 22 ± 2°C (12-h dark/light cycle), and had free access to food and water. The food was formed to a typical murine solid feed which firmed KGM powders. Food and water were changed fresh weekly.
Animal care was in compliance with the regulations of Hiroshima University.
Feeding
The mice were fed either with a commercial rodent diet, MF (Oriental Yeast, Tokyo, Japan), PA diet (MF containing 5 % (w/w) PA powder), or the PKGM diet (MF containing 5 % (w/w) PKGM powder) ad libitum. We started to presensitize the mice with OXA 2 weeks after the start of feeding with either diet. The food intake in the different experimental groups was similar because there was no difference in the body weights 2 weeks after the intake of each diet.
Induction of colitis
OXA colitis was induced as previously described, with minor modifications [15] . OXA (4-ethoxymethylene-2-phenyl-2-OXA-5-one) was obtained from Sigma-Aldrich (St. Louis, MO). To presensitize the mice, a 1.5 9 1.5 cm field of the abdominal skin was shaved, and 200 ll of a 3 % solution of OXA in 100 % ethanol or 100 % ethanol alone was applied. Five days after presensitization, the mice underwent general anesthesia with isoflurane and were rechallenged intrarectally with 150 ll 1 % OXA in 50 % ethanol or, for the control-fed mice, 50 % ethanol alone. To ensure distribution of OXA within the entire colon and cecum, mice were held in a head-down vertical position for 60 s after the intrarectal injection. Mice were then monitored for the appearance of diarrhea, loss of body weight, and overall mortality.
Histological examination of colitis
Colon samples were removed from mice at 5 days after induction of colitis. The colons were opened longitudinally and rolled concentrically. The tissues were then fixed in 10 % buffered formalin and embedded in paraffin. Paraffin sections were made and stained with hematoxylin and eosin.
Histological examination was evaluated as previously described [21] . The degree of inflammation and epithelial injury on microscopic cross-section was graded semiquantitatively on a scale of 0-6. Inflammatory cell infiltration was scored from 0 to 3, and tissue damage was scored from 0 to 3. Occasional or no inflammatory infiltrate in the lamina propria was scored as 0, increased numbers of inflammatory cells restricted to the lamina propria as 1, inflammatory infiltrates reaching the submucosa as 2, and transmural inflammation as 3. The tissue damage subscore took into account epithelial lesions: No mucosal damage was scored as 0, focal crypt lesions as 1, surface mucosal erosions or focal ulcerations as 2, and extensive mucosal damage affecting the submucosa as 3. The combined inflammatory and injury scores resulted in an overall score ranging from 0 (no changes) to 6 (severe inflammatory infiltrate and mucosal damage).
Isolation and purification of mononuclear cells
Mice were killed at 2 days after colitis induction, and hepatic mononuclear cells or lamina propria mononuclear cells (LPMCs) were isolated.
Hepatic mononuclear cells were isolated by grinding the tissue in a Petri dish and filtering the cell suspension through a 40-lm mesh. Mononuclear cells were isolated using 44 and 66 % solutions of Percoll.
LPMCs were isolated as previously described in detail [22, 23] . In brief, LPMCs were isolated after removal of epithelial cells by incubation of colon strips in Ca -free Hanks' balanced salt solution containing 1 mM EDTA (SigmaAldrich) for 15 min at 37°C. Mononuclear cells were released by digesting the tissue in RPMI-1,640 medium (Sigma-Aldrich) supplemented with 150 U/ml collagenase (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and incubated for 1.5 h at 37°C with stirring. Finally, leukocytes were separated from epithelial cells by centrifugation in 44 and 66 % solutions of Percoll (pH 8.5-9.5) (Sigma-Aldrich).
Cell culture for cytokine production The cells were harvested and stimulated in vitro with 5 lg/ml of plate-bound anti-CD3 antibody (145-2C11) (BD Biosciences Pharmingen, San Diego, CA), 5 lg/ml of PMA ? ionomycin, or Con A for 48 h at 37°C. Supernatants were collected and stored at -80°C until further analysis.
ELISA assays
Cytokine concentrations in culture supernatants were measured by ELISA kits according to the manufacturers' instructions. IFN-c, TNF-a, and IL-4 were measured with OptEIA ELISA sets (BD Biosciences Pharmingen), and IL-13 was measured with Quantikine M ELISA kit (R&D Systems, Minneapolis, MN).
FACS analysis
Cells were stained with antibodies to CD3 (17A2) and NK1.1 (NKR-P1B and NKR-PIC). Surface staining cells were analyzed using a fluorescence-activated cell sorting (FACS) Calibur system (BD Biosciences). Percentage values were calculated with CellQuest software (BD Biosciences) from the scatter plots, which were attained with propidium iodide (Sigma-Aldrich) staining after gating on living lymphocytes.
Statistical analysis
Data are expressed as mean ± SD of N observations. All values in the figures and text were analyzed with the Japanese version of JMP (SAS Institute Inc., Cary, NC, USA), and the data sets were examined with one-way ANOVA. Differences were considered significant at p \ 0.05.
Results
Preventive role of dietary PKGM in OXA-induced colitis
To examine the role of PKGM in the development of OXA-induced colitis in vivo, we administrated the chow containing 5 % PKGM or 5 % PA to C57BL/6 mice for 14 days before OXA treatment. Two days after rectal administration of OXA, PKGM-fed mice had lost about 12 % of their initial body weight. However, PKGM-fed mice showed a significant improvement in body weight from day 4 to day 5 after 1 % OXA administration as indicated in Fig. 1a (p \ 0.05) . PA-fed mice recovered their body weight loss later than PKGM-fed mice. Macroscopic examinations on day 5 after 1 % OXA administration revealed that shortening of colon length was significantly more inhibited in PKGM-fed mice than in control or PA-fed mice (Fig. 1b, c; p \ 0.05) . The colons of control or PA-fed mice were more reddish due to bloody stool compared with those of PKGM-fed mice, suggesting that a less severe intestinal inflammation had occurred in the PKGM-fed mice (Fig. 1b) . On histological examination of involved colon in the 1 % OXA-treated PKGM-fed mice, we observed a superficial inflammation characterized by the presence of epithelial cell loss, patchy ulceration, pronounced depletion of mucin-producing goblet cells, and a reduction in the density of the tubular glands. These histopathological changes in OXA-induced colitis were significantly less severe in the colon of PKGM-fed mice than in control and PA-fed mice on day 5 after 1 % OXA administration ( Fig. 1d, e ; p \ 0.05). These data suggest that treatment with dietary PKGM prevents intestinal inflammation induced by OXA.
Cytokine production of PKGM-fed mice with oxazolone-induced colitis To investigate whether PKGM treatment has immunological modulations, we examined production of local cytokines. Pro-inflammatory cytokine TNF-a from the mononuclear cells of the colon was induced by OXA colitis, which was suppressed by the administration of PKGM (Fig. 2a, p \ 0.05) . The mononuclear cells from colon of mice administered OXA produced IL-4 and IL-13, major Th2 cytokines, which were also significantly inhibited by feeding with PKGM ( Fig. 2b, c ; p \ 0.05). No change in the level of Th1 cytokine IFN-c from LPMCs was observed in OXA colitis LPMCs (Fig. 2d) . When we compared the IL-4/IFN-c ratio, a significantly lower ratio was found in the PKGM-fed mice versus the control-fed mice in LPMCs (Fig. 2e) . These data raise the possibility that PKGM has a capacity to suppress Th2-related but not Th1-related cytokines induced by OXA.
Effect of PKGM treatment on NK1.1 ? T cell population
To identify the target cells involved in the prevention OXA-induced colitis in PKGM-fed mice, we isolated lymphocytes from liver and colon and investigated a surface antigen of the cells. Flow cytometric analysis revealed that the frequency of NK1.1
? T cells significantly decreased in liver of the PKGM-fed mice compared with that observed in liver of control or PA-fed mice ( Fig. 3 Treatment of these mice with rectal application of OXA resulted in similar weight loss pattern (Fig. 4a ) and colon shortening (Fig. 4b) between PKGM-fed mice and PA-fed mice because of massive inflammation of the colonic tissue (Fig. 4c, d) . In this experimental model, PKGM was unable to reverse local signs of inflammation caused by OXA administration. Although the levels of TNF-a in the colon were significantly increased after OXA treatment (Fig. 5a) , no increase was found in the levels of IL-4 or IL-13 in the colon (Fig. 5b, c) . Moreover, IFN-c secretion was not induced by OXA treatment (Fig. 5d) , and the Th1/Th2 ratio did not change by PKGM treatment (Fig. 5e ). These data suggested that mechanisms other than induction of IL-13 or skewing of the Th1/Th2 ratio may be involved in the intestinal inflammation produced in KO mice by OXA. These findings suggest that PKGM, at least partially, acts directly on iNKT cells in vivo.
Discussion
In this study, we showed that PKGM was effective for the prevention of Th-2-mediated OXA colitis by skewing the Th1/Th2 balance from Th2 toward Th1. PKGM decreased the population of NK1.1
? T cells. The protective effect of PKGM against OXA colitis was absent in the presence of iNKT cell deficiency.
Konjac is known to be a healthy, traditional food in Japan and several other Asian countries. KGM is a polysaccharide, which is used as food in paste or coagulated form. KGM itself is a soluble dietary fiber, but the coagulated form of KGM is not water soluble and has strong elasticity. Thus, KGM is popular as a dietary food because Eur J Nutr (2015) 54:959-969 963 of its very low caloric value and the large amount of dietary fiber it provides. KGM is not degradable by human digestive enzymes but is available to be partially converted to a fatty acid by the intestinal microflora [7] . Moreover, it has been reported that KGM blocks the absorption of cholesterol in the small intestine and maintains a lower plasma cholesterol level [6] , and it is effective in protecting against diabetes because KGM suppresses the rapid absorption of glucose from the upper small intestine, thus sparing the secretion of insulin [24] . It is also reported that KGM has a therapeutic effect on human and mouse dermatitis. Oral intake of konjac ceramide improves both skin symptoms in children with AD and allergen-specific IgE production with skewing of the cytokine pattern toward the Th1 type in allergenstimulated cultures [25] . Oral intake of konjac-derived glucosylceramide improved skin roughness caused by SDS treatment in mice [26] .
The KGM that has been used until now, however, has high viscosity and low solubility that requires long time intervals to attain peak viscosity. Therefore, we prepared various particle sizes of low viscous and highly specific surface area of the KGM molecule that would be expected to possess the more effect of these well-known physiological activities. Production of IL-4 and IFN-c in splenocytes of NC/Nga mice, an experimental model of human AD, was decreased in the PKGM-fed mice, and AD-like skin symptoms were markedly suppressed by oral intake of PKGM [11, 12] . Soluble PKGM suppressed IgE production in splenocytes of mice in vitro [27] . Both the Th1 and Th2 cytokines play important roles in AD [28] , and Th2-specific chemokines are overproduced in NC/Nga mice [29] . OXA colitis is a well-known experimental model of human UC. Rectal administration of the hapten reagent OXA induces a severe colitis in mice that is characterized by weight reduction and diarrhea and which leads to high death rates [15] . Superficial inflammation includes epithelial cell loss and patchy ulceration as well as pronounced depletion of goblet cells accompanied by a mixed inflammatory infiltrate of lymphocytes and granulocytes. This inflammation is characterized by increased IL-4 and IL-13 secretion and can be ameliorated by the administration of anti-IL-4 or anti-IL-13 monoclonal antibodies [15] . In the present study, PKGM suppressed exacerbation of OXA colitis. PKGM but not PA specifically suppressed body weight loss, shortening of colon length, and histological inflammation of the colon. PKGM and PA have been shown to have different immunological effects. Onishi et al. [9] showed that PKGM but not PA suppressed IL-4 and IFN-c from spleen cells in mice. We suppose that PKGM, with a smaller particle size than that of KGM, might gain its protective effect because it possesses a lower viscosity and has higher absorbance in the intestine, although the mechanisms are not fully understood.
The exact mechanisms by which PKGM but not PA induces immunosuppression are also not completely understood. In the present study, we clearly showed that PKGM substantially reduced the inflammatory response. PKGM treatment decreased Th2 cytokine levels such as those of IL-4 and IL-13, but there was no change in levels of IFN-c, known as a Th1 cytokine. PKGM suppressed the levels of IL-4 production in ConA-stimulated mononuclear cells in vitro, indicating that the effect of PKGM on Th2 cells may directly affect Th2 differentiation rather than lymphocyte trafficking. The Th2/Th1 ratio, represented by the IL-4/IFN-c ratio, was significantly lower in the PKGMfed mice relative to the control and PA-fed mice. We also found that PKGM suppressed IL-13 from mononuclear cells in the colon. It is well known that IL-13 is a key cytokine in OXA-induced colitis [5] and is an important effector cytokine in human UC that impairs epithelial barrier function by affecting epithelial apoptosis, tight junctions, and restitution velocity [30] . Recent studies found that IFN-b-1a suppresses inflammation in human UC by inhibiting IL-13 production [31] and that colitis and intestinal inflammation in IL10-/-mice resulted from IL13Ra2-mediated attenuation of IL-13 activity [32] . In the present study, the reduction in IL-13 was already shown on day 2 after 1 % OXA administration, and we have proved that PKGM suppressed OXA colitis because of the decrease in IL-13 production.
Moreover, we examined which subset of cells was influenced by PKGM in OXA-induced colitis. Interestingly, the population of NK1. has been widely studied [33, 34] , and the role of noninvariant NKT cells in the pathogenesis of human UC and OXA colitis in mice has been reported. Further investigation is required to reveal the mechanism by which PKGM decreases iNKT cells.
To determine whether the immune compartment mediates the effect of PKGM in vivo, we examined the effect of PKGM in OXA colitis in iNKT cell-deficient mice. Interestingly, OXA colitis was also induced in iNKT celldeficient mice with local colonic TNF-a induction. Moreover, we found that neither IL-4 nor IL-13 was elevated in the colon of iNKT cell-deficient mice after OXA treatment. These data suggested that mechanisms other than induction of IL-13 or skewing of the Th1/Th2 ratio may be involved in the intestinal inflammation induced by OXA in KO mice. Finally, we also found that in comparison with control-fed mice, PKGM exerted no effective role in iNKT cell-deficient mice, strongly suggesting that the iNKT cell Data represent the mean ? SD of 6 mice per group. This experiment was repeated three times population could be a target for this agent. These findings further suggest that PKGM, at least partially, acts directly on iNKT cells in vivo. In UC, the main producer of IL-13 is not iNKT cells but non-invariant NKT cells [19] . Further investigation will be required to elucidate whether both invariant and non-invariant NKT cells are influenced by PKGM.
Conclusion
In summary, we have provided evidence that PKGM exerts anti-inflammatory activities in a mouse model of OXA-induced colitis by targeting, among other mechanisms, lamina propria T cells. In light of the fact that therapeutic approaches for inhibiting T cell proliferation such as glucocorticoids, azathioprine/6-MP, and anti-TNF-a antibodies are effectively used to treat UC, our results support the notion that PKGM might be added to the list of compounds that have utility in the treatment of UC.
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